Aspergillus galactomannan antigen for diagnosis and treatment monitoring in cerebral aspergillosis

Progress in Transplantation

Volumn 23, Issue 1, 2013, Pages 71-74

  Soeffker, Gerold ^a   Wichmann, Dominic ^a   Loderstaedt, Ulrike ^a   Sobottka, Ingo ^a   Deuse, Tobias ^b   Kluge, Stefan ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HEART CENTER HAMBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; DIAGNOSTIC AGENT; FUNGUS ANTIGEN; GALACTOMANNOPROTEIN, ASPERGILLUS FUMIGATUS; MEMBRANE PROTEIN; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ARTICLE; CASE REPORT; CENTRAL NERVOUS SYSTEM ASPERGILLOSIS; CEREBROSPINAL FLUID; DRUG MONITORING; EARLY DIAGNOSIS; ENZYME IMMUNOASSAY; FUNGAL MENINGITIS; HEART TRANSPLANTATION; HUMAN; MALE; METHODOLOGY; MIDDLE AGED;

ANTIFUNGAL AGENTS; ANTIGENS, FUNGAL; DRUG MONITORING; EARLY DIAGNOSIS; HEART TRANSPLANTATION; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MEMBRANE GLYCOPROTEINS; MENINGITIS, FUNGAL; MIDDLE AGED; NEUROASPERGILLOSIS; PYRIMIDINES; TRIAZOLES;

MLCS; MLOWN;

EID: 84874676088     PISSN: 15269248     EISSN: None     Source Type: Journal    
DOI: 10.7182/pit2013386     Document Type: Article

References (19)

1. Moling O, Lass-Floerl C, Verweij PE, et al. Case Reports. Chronic and acute Aspergillus meningitis. Mycoses. 2002; 45(11-12):504-511.
2. Nenoff P, Kellermann S, Horn LC, et al. Case report. Mycotic arteritis due to Aspergillus fumigatus in a diabetic with retrobulbar aspergillosis and mycotic meningitis. Mycoses. 2001; 44(9-10):407-414.
3. Verweij PE, Brinkman K, Kremer HP, Kullberg BJ, Meis JF. Aspergillus meningitis: diagnosis by non-culture-based microbiological methods and management. J Clin Microbiol. 1999; 37(4):1186-1189.
4. Laurencikas E, Sandstedt B, Söderman M. Intrathecal aspergillosis and fusiform arterial aneurysms in an immunocompromised child: A clinico-pathological case report. Childs Nerv Syst. 2006;22(11):1497-1501.
5. Pagano L, Ricci P, Montillo M, et al. Localization of aspergillosis to the central nervous system among patients with acute leukemia: report of 14 cases. Gruppo Italiano Malattie Ematologiche dell'Adulto Infection Program. Clin Infect Dis. 1996; 23(3):628-630.
6. Walsh TJ, Hier DB, Caplan LR. Aspergillosis of the central nervous system: clinicopathological analysis of 17 patients. Ann Neurol. 1985;18(5):574-582.
7. Klont RR, Mennink-Kersten MA, Verweij PE. Utility of Aspergillus antigen detection in specimens other than serum specimens. Clin Infect Dis. 2004;39(10):1467-1474.
8. Verweij PE, Dompeling EC, Donnelly JP, Schattenberg AV, Meis JF. Serial monitoring of Aspergillus antigen in the early diagnosis of invasive aspergillosis. Preliminary investigations with two examples. Infection. 1997;25(2):86-89.
9. Viscoli C, Machetti M, Gazzola P, et al. Aspergillus galactomannan antigen in the cerebrospinal fluid of bone marrow transplant recipients with probable cerebral aspergillosis. J Clin Microbiol. 2002;40(4):1496-1499.
10. Meersseman W, Lagrou K, Maertens J, et al. Galactomannan in bronchoalveolar lavage fluid: A tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med. 2008;177(1):27-34.
11. Luong ML, Clancy CJ, Vadnerkar A, et al. Comparison of an Aspergillus real-time polymerase chain reaction assay with galactomannan testing of bronchoalvelolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in lung transplant recipients. Clin Infect Dis. 2011;52(10):1218-1226.
12. Antinori S, Ridolfo AL, Galimberti L, et al. Usefulness of serial determination of Aspergillus galactomannan in the diagnosis and management of invasive aspergillosis in an AIDS patient with non-Hodgkin lymphoma [published online ahead of print June 14, 2011]. Mycoses. doi:10.1111/j.1439-0507.2011. 02034.x.
13. Kami M, Ogawa S, Kanda Y, et al. Early diagnosis of central nervous system aspergillosis using polymerase chain reaction, latex agglutination test, and enzyme-linked immunosorbent assay. Br J Haematol. 1999;106(2):536-537.
14. Mikulska M, Furfaro E, Del Bono V, et al. Piperacillin /tazobactam (TazocinTM) seems to be no longer responsible for false-positive results of the galactomannan assay [published online ahead of print April 11, 2012]. J Antimicrob Chemother. doi: 10.1093/jac/dks111.
15. Schwartz S, Ruhnke M, Ribaud P, et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood. 2005;106(8):2641-2645.
16. Miyakis S, van Hal SJ, Ray J, Marriott D. Voriconazole concentrations and outcome of invasive fungal infections. Clin Microbiol Infect. 2010;16(7):927-933.
17. Hamada Y, Seto Y, Yago K, Kuroyama M. Investigation and threshold of optimum blood concentration of voriconazole: A descriptive statistical meta-analysis [published online ahead of print January 11, 2012]. J Infect Chemother. 2012;18(4):501-507.
18. Trifilio S, Ortiz R, Pennick G, et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2005;35(5):509-513.
19. Lat A, Thompson GR 3rd. Update on the optimal use of voriconazole for invasive fungal infections [published online ahead of print February 3, 2011]. Infect Drug Resist. 2011; 4:43-53.